Novo hikes guidance on Wegovy pill’s fast sales start
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
ORIGINAL SOURCE →via Biopharma Dive
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · DK
- [CONFLICT] Temenos Community Forum 2026: Embracing progressive digital banking
- [FINANCE] Denmark’s central bank picks Tieto for document management - FinTech Global
- [FINANCE] Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
- [CONFLICT] Maersk says ship passed through Strait of Hormuz under U.S. military protection
- [TECH] Denmark presses pause on new data center grid connections as total requests hit 60 GW — Nordic nation is the latest to put the brakes on AI buildouts
- [ENERGY] Vestas Profit Rises on Offshore Ramp-Up, Warns on Risks